On January 23, 2018, the United States Court of Appeals for the Federal Circuit handed down In re Janssen Biotech, Inc.,[1] which dealt with the specific issue of the double patenting safe harbor under 35 U.S.C. §121.[2] This case is an example of playing games with the patent prosecution system in order to better position …
